Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Male, 25-85 years old

Exclusion Criteria:

• Current users of bisphosphonates such as Aredia® (pamidronate), Didronel® (etidronate), Fosamax® (alendronate), Actonel ® (residronate), Skelid® (tiludronate)

• History of severe liver, kidney or eye disease

Other protocol-defined inclusion/exclusion criteria may apply.